Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is largely considered to be one of the primary mechanisms driving disease progression in B–Cell lymphomas. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.